Performance of ENMC and EULAR/ACR classification systems applied to a single tertiary center cohort of dermatomyositis patients

Jan Zoske1, Udo Schneider2, Elise Siegert2,3, Felix Kleefeld4, Corinna Preuße5, Werner Stenzel5† and Katrin Hahn4*†

Abstract

Background: There have been numerous classification systems to diagnose corresponding myositis subtypes and select appropriate therapeutic measures. However, the lack of a broad consensus on diagnostic criteria has led to clinical uncertainties. The objective of this study was to compare two commonly used dermatomyositis-classification systems regarding their clinical practicability and to point out their specific advantages and disadvantages.

Methods: This study included 30 patients diagnosed with dermatomyositis at the Charité university hospital, Berlin, Germany from 2010 to 2017. Patient files with complete data and defined historical classifications were enrolled and ENMC (2003) and EULAR/ACR (2017) criteria retrospectively applied.

Results: According to the ENMC approach, 14 patients were classified as "definite" and 12 as "probable" dermatomyositis. One patient exhibited an "amyopathic dermatomyositis" and three a "DM without dermatitis". Regarding the criteria probability of the EULAR/ACR set, 16 patients had a "high", 13 a "medium" and one a "low probability". There was a significant difference (p = 0.004) between the subclasses of the ENMC in relation to the EULAR/ACR score. The agreement between the classification probabilities of "definite/high" (κ = 0.400) and "possible/medium" (κ = 0.324) was fair.

Conclusions: It is important to find a consensus among the medical disciplines involved and to establish a structured procedure. Future studies with newer approaches are warranted to conclusively decide which system to use for the physician.

Keywords: Dermatomyositis, ENMC, EULAR/ACR, Idiopathic inflammatory myositis, Muscle biopsy

Introduction

Idiopathic inflammatory myopathies (IIM) are rare heterogeneous diseases characterized by inflammation in the skeletal muscles and resulting muscle weakness [1]. They frequently involve other organs such as the skin, joints, lungs or heart [2–4]. Depending on the clinical phenotype, the histomorphological findings and the involvement of other organs, different subtypes can be classified. A widely accepted basis is the 1975 description by Bohan and Peter for polymyositis (PM) and dermatomyositis (DM) [5, 6]. They defined for the first time the need of a clear classification and created the basis for the development of modern myositis classification systems. Even today, the core statements of their criteria are still part of various classification systems and are still commonly used [7]. In 2003, the European Neuromuscular Centre (ENMC) international...
workshop (2003 ENMC–IIM) revised dermatomyositis, polymyositis and inclusion body myositis (IBM) classification and proposed two additional categories. These are called immune-mediated necrotising myopathy (IMNM) and non-specific myositis. The aim was to be able to further differentiate IIM according to a possible different pathogenesis [8, 9]. In 2017, new dermatomyositis classification criteria according to the European League against Rheumatism (EULAR) and the American College of Rheumatology (ACR) were proposed which were validated through 976 patients with idiopathic inflammatory myopathies as well as 624 non-myopathic controls [10, 11]. Historically, the classifications are subject to a dynamic process, which is mainly based on new findings in the fields of immunology and pathology [12, 13]. Over the last few decades, there have been numerous classification systems with different focuses. However, the lack of a broad clinical consensus has resulted in diagnostic uncertainties in clinical practice for many physicians, especially those who do not deal with the latest findings on a daily basis and need clear guidelines [12, 14]. This individual change in diagnostics is evident in the systems used and compared in this study. They are characteristic of the classification criteria that have been adapted in different ways.

Dermatomyositis can be clinically identified by a characteristic dermatological phenotype such as the heliotrope rash and Gottron’s papules or Gottron’s sign. The patients frequently exhibit a progressive symmetrical muscle weakness of the upper and lower proximal musculature. Nevertheless, this typical clinical picture can be considered rare with a fluctuating incidence of 2–9/1,000,000 depending on the population [15, 16]. Over the last few decades, several DM-specific autoantibodies have been discovered and each of these has been associated with a unique clinical phenotype [17, 18]. The different subtypes differ in terms of both therapeutic response and prognosis of the disease, so that a clear assignment is of considerable clinical relevance [19].

The aim of this study is to compare ENMC and EULAR/ACR classifications retrospectively.

**Materials and methods**

**Study design**

This was a retrospective study conducted in the departments of Neurology and Rheumatology of the Charité university hospital. All study procedures were in accordance with the 1964 Helsinki declaration and its later amendments. The Medical Ethics Committee had approved the study (EA4/053/17).

**Study population**

We screened electronic hospital files from 2010 to 2017 retrospectively for “International Statistical Classification of Diseases and Related Health Problems” (ICD)-10 codes (M33.0, M33.1, M33.2, M33.9, M35.1, M60.8) corresponding to the different subtypes of myositis. Figure 1 summarizes the screening process.

To provide a solid basis for the selection of the patient collective, all myositis patient cases (n = 100) were reviewed with regard to the myositis diagnosis made and their findings. We identified 44 patients with suspected DM. Applicability of the ENMC and EULAR/ACR criteria was mandatory for our analysis. Patients with inaccurate, very incomplete or missing documentation were excluded. This also included patients whose DM diagnosis was changed during treatment. Patients who did not return after their first visit were also removed from our analysis. In the end, we obtained a strictly selected group of 30 DM patients.

**Outcome assessments**

The same person carried out the data collection as well as the application of the classification systems.

The patient classification and, if included in the sets, the statement on the criteria probability were carried out strictly according to the specifications of the respective systems. Figure 2 summarizes the classification options.

**Patient classification according to ENMC (2003)**

The decision on classification was based on the combination of clinical myogenic as well as clinical dermatological, histopathological, serological and other findings, like electromyography (EMG) or magnetic resonance imaging (MRI) [9]. A "definite dermatomyositis" can be classified if all clinical criteria are met and if perifascicular atrophy is found in the histopathological diagnosis. A "probable DM" is diagnosed by the presence of all clinical criteria and the presence of one of the three following findings: This includes the histopathological picture of a myopathic pattern and/or perivascular and perimysial inflammatory cell infiltrates. The second finding relates to elevated serum creatine kinase levels and the third to abnormal findings of the "other laboratory criteria" (EMG, electrocardiography, myositis-specific antibodies). "Amyopathic dermatomyositis" is classified according to the ENMC set if the following typical combination of clinical and laboratory findings can be described: Although a typical dermatological picture occurs, there is no objective muscle weakness. A normal serum CK and normal EMG findings can be detected. The muscle biopsy finding shows no abnormalities of a "definite" or "probable" DM. A characteristic feature is the finding of a
reduced capillary density, the accumulation of membrane attack complex (MAC) on small blood vessels along the dermal–epidermal junction and a variable keratinocyte decoration in the examination of a skin biopsy. The last subclass of "possible DM sine dermatitis" is classified if a typical pattern of histopathological (perifascicular atrophy; MAC deposits), serological and "other laboratory criteria" and clinical findings (excluding dermatological characteristics) is observed.

Patient classification according to EULAR/ACR (2017)

The use of the EULAR/ACR set was carried out in the sense of the model system “with” or “without” the use of a muscle biopsy with 16 included variables [20]. Due to the pre-selection of the patient cohort, it was not necessary to use the EULAR/ACR classification tree to assign a subgroup of IIM. The Web-based calculator was used to assign findings to a score range, probability, and classification [21]. The most important aspects, namely the age of manifestation, the distribution pattern of the paresis, the dermatological findings, laboratory values, other organ manifestations, and the histomorphology of the muscle are considered. An overall score is derived, which is then converted into a percentage probability value and assigned to the probability categories. Those are a “high probability” (≥90%), “possible IIM/medium probability” (10–90%) and "low probability" (≤10%). For the purpose of comparability with the ENMC system, patients with a percentage probability below the cut-off level of ≥55% are also assigned and classified.

Statistical analysis

We used descriptive statistics to describe demographic variables and categorical variables as statistical frequencies. Unless stated otherwise, the percentages refer to the entire cohort of 30 DM patients. To describe the metric variables, median, first and third quartile as well as maximum and minimum are given.

Due to the skewed distribution of almost all metric variables, non-parametric tests were applied regarding the comparison of the classification systems for group and pairwise comparisons. The Kruskal–Wallis test was used as the overall test for the comparisons between the four classification groups (ENMC: certain; probable; amyopathic; DM without dermatitis) and the EULAR/ACR score. In the case of a significant result in this test, the Mann–Whitney U test was used as a posthoc test for pairwise comparison. In order to be able to make a
statement about their agreement, the Cohen’s Kappa (κ) agreement measure was collected in relation to the criteria probabilities (ENMC: certain; probable / EULAR/ACR: high; medium).

Statistical analyses were performed using IBM SPSS Statistics 26 statistical software. *p* values < 0.05 were considered statistically significant.

**Results**

**General findings**

As part of the review of the diagnostics carried out and their findings, it was possible to describe statements on the diagnostic procedures used as well as the various clinical features of the DM patients. Table 1 shows an overview of those results.

**Patient classification according to ENMC (2003)**

Among the 30 patients considered, 46.7% (*n* = 14) could be classified as "definite" and 40% (*n* = 12) as "probable dermatomyositis". Only one patient was classified as "amyopathic dermatomyositis" and three (10%) as "possible DM sine dermatitis".

**Patient classification according to EULAR/ACR (2017)**

Regarding the entire patient cohort, including patients with and without muscle biopsy, the median value of the probability score is 9.1 with a range of 5.1–13.4 (Q1: 7.28 / Q3: 11.45). This corresponds to a "high" probability of diagnosis.

24 out of 30 DM patients (80%) had received a muscle biopsy. Regarding the total score of these patients, the median value is 9.95 with a range of 5.1–13.4 (Q1: 7.83 / Q3: 12.28). This corresponds to a percentage probability of about 88% reflecting a "high" criteria probability.

Six patients without a muscle biopsy taken reached a median value of 7.2 with a range of 6.0–8.0 (Q1: 6.53 / Q3: 7.48). This corresponds to a percentage probability of about 82% reflecting a "medium" criteria probability.

**Classification systems in comparison**

As the results of the two approaches suggest, this study shows a variety of possible combinations between the respective classification statements. Those eight combinations are listed in Table 2 and shown in number and percentage ratio:

---

![Classification systems](image-url)
Combinations 1 and 4, which are congruent in their statements, make up the majority of patient cases here (n = 19/30). As can be seen in the table, there is a heterogeneous range of combinations. The agreement between the classification probabilities of "definite/high" (κ = 0.400) and "possible/medium" (κ = 0.324) was fair.

In Fig. 3 the individual ENMC subclasses can be compared with the EULAR/ACR score. For "definite DM", the median score is 11.7 with minimum and maximum scores of 7.2 and 13.4. "Probable DM" was characterized by a median score of 7.7 with minimum and maximum scores of 6.0 and 10.3. "Amyopathic DM" was only found in one patient; therefore, the EULAR/ACR score of 7.3 reflects a single value. The median score of 7.7 together with the minimum and maximum scores of 5.1 and 9.7 describes the relationship between "possible DM sine dermatitis" and the EULAR/ACR score.

Furthermore, there is a significant difference (p = 0.004) between the individual subclasses of the ENMC in relation to the EULAR/ACR scores. The "definite DM" has a significantly higher score value than the "probable DM" (p = 0.001). In relation to "possible DM sine dermatitis" a significantly higher EULAR/ACR score was identified (p = 0.032). No significant

Table 1 Clinical features of patients with dermatomyositis

| Clinical feature                                | Value       |
|------------------------------------------------|-------------|
| Age (at diagnosis)                              | 54.23 years |
| Sex (female: male)                              | 2:3:1       |
| Proximal muscle weakness                        | 29 (96.7%)  |
| Raynaud                                         | 2 (6.7%)    |
| Dysphagia                                       | 6 (20.0%)   |
| Arthralgia/arthritis                            | 11 (36.7%)  |
| ILD                                             | 5 (16.7%)   |
| Cancer                                          | 8 (26.7%)   |
| ANA positivity                                  | 12 (40%)    |
| DM-specific antibodies (n = 17)                 | 12 (70.5%)  |
| Anti-Jo1 positivity (n = 28)                    | 0           |
| Ro52 (n = 27)                                   | 10 (37.0%)  |
| Elevated CK (n = 24)                            | 16 (66.7%)  |
| Cutaneous involvement                           |             |
| Heliotrope rash                                 | 27 (90.0%)  |
| Gottron’s papules                               | 6 (20.0%)   |
| Gottron’s sign                                  | 0           |
| Ro52                                            |             |
| Heliotrope rash                                 |             |
| Gottron’s papules                               |             |
| Gottron’s sign                                  |             |

Table 2 Comparison of the results of the classification systems

| Comb | ENMC (2003) | EULAR/ACR (2017) | Amount | %     | κ    |
|------|-------------|------------------|--------|-------|------|
| 1    | Definite DM | High probability | 11/30  | 36.7  | 0.400|
| 2    | Definite DM | Possible IIM     | 3/30   | 10    | –    |
| 3    | Probable DM | High probability | 4/30   | 13.3  | –    |
| 4    | Probable DM | Possible IIM     | 8/30   | 26.7  | 0.324|
| 5    | Possible DM | High probability | 1/30   | 0.03  | –    |
| 6    | Possible DM | Possible IIM     | 1/30   | 0.03  | –    |
| 7    | Possible DM | Low probability  | 1/30   | 0.03  | –    |
| 8    | Amyopathic DM| Possible IIM    | 1/30   | 0.03  | –    |

ILD interstitial lung disease, DM dermatomyositis, ANA antinuclear antibody, CK creatine kinase

ENMC European Neuromuscular Centre, EULAR European League Against Rheumatism, ACR American College of Rheumatology, DM dermatomyositis, IIM idiopathic inflammatory myopathies
difference could be shown in the combinations of the other ENMC subclasses in relation to the score value.

Discussion
The retrospective application of two different classification systems to patients with dermatomyositis enables for the first time a direct comparison of the approaches. While there are many different publications dealing specifically with the comparison of the classification systems with the original approach of Bohan and Peter [7, 22], a direct comparison of the currently established systems on a single tertiary center cohort is missing. The aim of the study was to evaluate the existing classification systems regarding their practicability, advantages and disadvantages as well as their basic concepts. The definition of a harmonized evaluation system with homogeneous case groups and clearly weighted diagnostic factors provides the basis for adequate medical patient care as well as clinical studies.

Advantages and disadvantages of classification systems
Practicability plays an important role and is crucial for a reliable diagnosis. Here it is defined by the quality of applying the classification systems retrospectively and simultaneously applying them into daily clinical use. In this respect, the EULAR/ACR approach can be favoured. The easily recognizable and clear structure of the classification [17] paves the way for structured diagnostics for every practitioner. Depending on the clinical and dermatological findings and additional review of laboratory measurements, a decision can be made as to whether a muscle biopsy is necessary. Nevertheless, it is important to distinguish between diagnostic criteria and classification criteria and to remember that classification criteria in the strict sense are not intended for diagnosis. They are developed based on findings in patients with established and well-defined disease and, when used as diagnostic criteria, can mislead the clinician.

Because the classification according to the "historical approach" of Bohan & Peter was not applied in this study and considering the small size of the patient cohort, no conclusions regarding sensitivity and specificity can be drawn here. At this point we refer to previously published data on sensitivity and specificity related to the two systems used [9, 20, 23]. In addition, we conclude that the diagnostic procedure of histopathological examination has a clearly positive effect on sensitivity and specificity.

Strengths and weaknesses can also be described in terms of focus and the criteria considered. The use of a minimum of clinical and readily available laboratory parameters seems questionable. The reason for this can be found in the emergence of the classification criteria [24]: The criteria were data-driven and based on patient and comparator data from many medical centers worldwide. A disadvantage is the weak and even often lacking consideration of diagnostic procedures such as antibody diagnostic, MRI or EMG. It must be said that especially the procedures of MRI and EMG considerably facilitate diagnosis, allow staging of the disease and can help in the selection of a suitable biopsy site. For this reason, Luu et al. showed that the inclusion of these procedures improves the accuracy of the probability of IIM diagnoses using the EULAR/ACR classification system [25]. However, the homogeneous distribution of the score points of the respective diagnostic parameters allows a wide range of observation of the patient cases [20]. Dermatological findings are considered highly significant and are characteristic or pathognomonic for dermatomyositis, except in special cases. For this reason, it is necessary to perform a muscle biopsy if the skin findings are inconspicuous or absent [26].

The ENMC criteria (2003) focus on muscle biopsy as the gold standard of diagnosis, combined with a set of clinical criteria [9]. A reliable diagnosis without the histopathological findings of perifascicular atrophy is inconceivable. It can be stated that there is no equal significance between the results of the diagnostic procedures and that the muscle biopsy is prioritized. At this point, reference should be made to the more recent DM-specific ENMC classification approach from 2018 [17]. This system follows the idea that DM autoantibodies are specific for DM and can be associated with a characteristic clinical phenotype, prognosis and response to treatment [27, 28]. The possibilities of antibody diagnostics
for classification of myositides were also discussed by Mariampillai et al. in 2018 [29]. They were able to show that myositis-specific antibodies are mainly important in the classification of myositis subtypes, whereas pathological data might be dispensable. They also refer to the EULAR approach and add the presence of four adjusted myositis entities to the classification system. Unfortunately, due to the frequent lack of antibody testing in the patients in our retrospective study, this was impossible. Data on applicability, sensitivity or specificity must be evaluated in the upcoming years.

Decision on classification according to ENMC and EULAR/ACR
The patient cohort was small but strictly selected. Because of the strict pre-selection, the classification scheme could have been influenced towards statements of higher criteria probabilities. Furthermore, the proportion of patients with "probable DM" must also be critically reflected upon, as this includes patients without a muscle biopsy. The possibility of "definite DM" remains open for half of the patients in this probability level due to the lack of a muscle biopsy.

Regarding the EULAR/ACR approach, the comparison of the two models "with" and "without muscle biopsy" must be discussed. Our results allow the statement that a muscle biopsy significantly increases the probability of a reliable diagnosis. The assessment of the criteria probability used here is slightly modified compared to the approach according to EULAR/ACR. The cut-off level of 55% was not considered here because of the aim of comparison. One patient case would have been excluded (Case-Nr. 13).

As already described, it can be asserted that patients tend to be assigned to the same criteria probability. This depends on their findings and independent of the chosen classification system. Adjusted for chance, the agreement in the sense of the definition according to Landis and Koch from 1977 [30] can be described as "fair".

A deviating classification of the diagnostic probability could be explained by the different structure of the systems. While the statement of a "definite" diagnosis according to ENMC is mainly based on the typical muscle biopsy and the clinical-dermatological statements, this combination of findings according to EULAR/ACR is only sufficient for a medium probability of criteria. Conversely, the ENMC classification cannot make any statements in the sense of a definitive DM in the absence of a muscle biopsy, but the EULAR/ACR approach can. The classification types of DM without dermatitis and amyopathic DM according to ENMC (2003) can be compared poorly with the statements according to EULAR/ACR, due to a lack of a statement on probability. Nevertheless, our study shows a heterogeneous range of combinations.

A general difficulty was the assignment of the clinical findings to the scoring system. The very precise definition of the parameters in combination with partially rather general descriptions allowed the possibility of wrong classifications and deviations in the score. In particular, the need for detailed documented clinical information led to a substantial reduction in the number of available cases.

Conclusion
The retrospective application of the ENMC (2003) and the EULAR/ACR (2017) classification to patients with dermatomyositis enables for the first time a direct comparison of the approaches. We did not show any inferiority of one of the two systems but a muscle biopsy significantly increases the probability of a reliable diagnosis. The question arises whether the need for routine histopathologic examination is still contemporary in clinical practice or whether other methods like antibody diagnostics could partly replace them. Similar to what has already been described by Zhang et al. (2019), the EULAR/ACR system has a high potential for being the classification system of the future [22]. However, it is important to find a consensus of the involved medical disciplines and to establish a structured procedure. It is currently up to the clinician to decide which approach to use based on experience and routine. It is therefore necessary to adapt to the available findings in order to be able to offer adequate care and therapy to the patient. A revision of the criteria is recommended in a few years' time, when more consistent serological information is available [17].

Abbreviations
ACR: American College of Rheumatology; DM: Dermatomyositis; EMG: Electromyography; ENMC: European Neuromuscular Centre; EULAR: European League against Rheumatism; IBM: Inclusion body myositis; IIM: Idiopathic inflammatory myopathies; IMNM: Immune-mediated necrotising myopathy; MAC: Membrane attack complex; MRI: Magnetic resonance imaging; PM: Polymyositis.

Acknowledgements
Not applicable.

Authors’ contributions
All authors contributed sufficiently to the work including conception and design (JZ, WS, KH), analysis (JZ) and interpretation of the data (JZ, WS, KH), drafting of the article (JZ, WS, KH), critical revision of the article for important intellectual content (US, ES, FK, CP), and final approval of the article (all). Integrity of the work is supported by all authors. Inquiries can be directed to the corresponding author. All authors read and approved the final manuscript.

Funding
Not applicable.
Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate
This study has been approved by the appropriate ethics committee (EA4/033/17) and has been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.

Consent for publication
Not applicable.

Competing interests
JZ, US, ES, FK, CP, WS declare that they have no competing interests. KH received financial reimbursement for consulting and advisory board activities and travel support to attend scientific meetings by Akcea Therapeutics Inc., Alnylam Pharmaceuticals Inc., Takeda Pharmaceutical Inc., Pfizer Pharmaceuticals Inc. and Swedish Orphan Biovitrum Inc. KH further received research funding by the foundation Chantê (Bih clinical fellow), Alnylam Pharmaceuticals Inc., and Pfizer Pharmaceuticals, all outside the submitted work.

Author details
1 Department of Periodontology, Oral Medicine and Oral Surgery, Charité - Universitätsmedizin Berlin, Humboldt-Universität Zu Berlin, and Berlin Institute of Health, 14197 Berlin, Germany. 2 Department of Neurology, Charité - Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany. 3 Berlin Institute of Health (BIH), Anna-Louisa-Karsch-Str. 2, 10178 Berlin, Germany. 4 Department of Neurology, Charité - Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany. 5 Department of Neuropathology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, and Berlin Institute of Health (BIH), Berlin, Germany.

Received: 6 September 2021   Accepted: 5 October 2021

Published online: 15 November 2021

References
1. Plotz, P.H., Rider, L.G., Targoff, I.N., Raben, N., O’Hanlon, T.P., & Miller, F.W. (1995). NIH conference. Myositis: Immunologic contributions to understanding cause, pathogenesis, and therapy. Annals of Internal Medicine, 122(9), 715–724. https://doi.org/10.7326/0003-4819-122-9-199501010-00010
2. Long, K., & Danoff, S.K. (2019). Interstitial lung disease in polymyositis and dermatomyositis. Clinics in Chest Medicine, 40(3), 561–572. https://doi.org/10.1016/j.ccm.2019.05.004
3. Lundberg, I.E. (2006). The heart in dermatomyositis and polymyositis. Rheumatology (Oxford), 45(Suppl 4), 18–21. https://doi.org/10.1093/rheumatology/kei311
4. Citera, G., Goni, M.A., Maldonado Cocco, J.A., & Scheines, E.J. (1994). Joint involvement in polymyositis/dermatomyositis. Clinical Rheumatology, 13(1), 70–74. https://doi.org/10.1007/BF02298688
5. Bohan, A., & Peter, J.B. (1975). Polymyositis and dermatomyositis (first of two parts). The New England Journal of Medicine, 297(7), 344–347. https://doi.org/10.1056/NEJM197502132920707
6. Bohan, A., & Peter, J.B. (1975). Polymyositis and dermatomyositis (second of two parts). The New England Journal of Medicine, 298(8), 403–407. https://doi.org/10.1056/NEJM197502202920807
7. Pinto, B., Janardana, R., Nadig, R., Mahadevan, A., Bhatt, A.S., Raj, J.M., & Shobha, V. (2019). Comparison of the 2017 EULAR/ACR classification criteria with Bohan and Peter criteria for the classification of idiopathic inflammatory myopathies. Clinical Rheumatology, 38(7), 1931–1934. https://doi.org/10.1007/s10067-019-04512-6
8. Tanооn, J., & Nishino, I. (2019). Classification of idiopathic inflammatory myopathies: Pathology perspectives. Current Opinion in Neurology, 32(5), 704–714. https://doi.org/10.1097/WCO.0000000000000740
9. Hoogendijk, J.E., Amato, A.A., Lecky, B.R., Choy, E.H., Lundberg, I.E., Rose, M.R., Vencovsky, J., de Visser, M., & Hughes, R.A. (2004). 119th ENMC international workshop: Triad design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10–12 October 2003, Naarden, The Netherlands. Neuromuscular Disorders, 14(5), 337–345. https://doi.org/10.1016/j.nmd.2004.02.006
10. Lundberg, I.E., Tjarnlund, A., Bottai, M., Werth, V.P., Pilkington, C., de Visser, M., …, Repository. (2017). 2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Arthritis Rheumatology. https://doi.org/10.1002/art.40320
11. Lundberg, I.E., Tjarnlund, A., Bottai, M., Werth, V.P., Pilkington, C., de Visser, M., …, Repository. (2017). 2017 European League Against Rheumatism/ American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Annals of the Rheumatic Diseases, 76(12), 1955–1964. https://doi.org/10.1136/annrheumdis-2017-211468
12. Leclair, V., & Lundberg, I.E. (2018). New myositis classification criteria—What we have learned since Bohan and Peter. Current Rheumatology Reports, 20(4), 18. https://doi.org/10.1007/s11926-018-0726-4
13. Sudan, S.M., & Isenberg, D.A. (2010). Re-classifying myositis. Rheumatology (Oxford), 49(5), 831–833. https://doi.org/10.1093/rheumatology/kep355
14. Wolstencock, P.W., & Fiorentino, D.F. (2018). Dermatomyositis clinical and pathological phenotypes associated with myositis-specific autoantibodies. Current Rheumatology Reports, 20(5), 28. https://doi.org/10.1007/s11926-018-0733-5
15. Bendewald, M.J., Wetter, D.A., Li, X., & Davis, M.D. (2010). Incidence of dermatomyositis and clinically amyopathic dermatomyositis: A population-based study in Olmsted County, Minnesota. Archives of Dermatology, 146(1), 29–30. https://doi.org/10.1001/archdermatol.2009.328
16. McCann, L.J., Juggins, A.D., Maillard, S.M., Wedderburn, L.R., Davidson, J.E., Murray, K.J., …, Juvenile Dermatomyositis Research, G. (2006). The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland)—Clinical characteristics of children recruited within the first 5 yr. Rheumatology (Oxford), 45(10), 1255–1260. https://doi.org/10.1093/rheumatology/keo099
17. Mammen, A.L., Allenbach, Y., Stenzel, W., Benveniste, O., Allenbach, Y., Benveniste, O., De Bleeker, J., Boyer, O., Casciola-Rosen, L., Christopherson, L., Danoiseux, J., Gitiaux, C., Fujimoto, M., Lamb, J., Landon-Cardinal, O., Lundberg, I.E., Mammen, A., Nishino, I., Radke, J., Werth, V. (2020). 239th ENMC International Workshop: Classification of dermatomyositis, Amsterdam, the Netherlands, 14–16 December 2018. Neuromuscular Disorders, 30(1), 70–92. https://doi.org/10.1016/j.nmd.2019.10.005
18. Zampeli, E., Venetsanopoulou, A., Argyropoulou, O.D., Mavragani, C.P., Taktoridou, M.G., Vlachoyiannopoulos, P.G., Tsoufas, A.G., Skopoul, F.N., & Moutsopoulos, H.M. (2019). Myositis autoantibody profiles and their clinical associations in Greek patients with inflammatory myopathies. Clinical Rheumatology, 38(1), 125–132. https://doi.org/10.1007/s10067-018-4267-z
19. Malik, A., Hayat, G., Kalia, J.S., & Guzman, M.A. (2016). Idiopathic inflammatory myopathies: Clinical approach and management. Frontiers in Nutrition, 7, 64. https://doi.org/10.3389/fnutr.2016.00064
20. Lundberg, I.E., & Tjarnlund, A. (2018). Response to “2017 EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: Little emphasis on autoantibodies, why?” by Malaviya. Annals of the Rheumatic Diseases, 77(11), e78. https://doi.org/10.1136/annrheumdis-2017-212709
21. Web-based Calculator: Classification criteria for idiopathic inflammatory myopathies. Retrieved September 29, 2021, from, http://www.imm.kuleuven.be/biostatistics/calculators/idsm
22. Zhang, X., Yang, X., Ji, L., & Zhang, Z. (2019). Validation of 2017 classification criteria for adult and juvenile idiopathic inflammatory myopathies proposed by EULAR/ACR in Chinese patients. International Journal of Rheumatic Diseases, 22(7), 1278–1282. https://doi.org/10.1111/1756-185X.13605
23. Barotti, S., Dastmalchi, M., Notarnicola, A., Leclaire, V., Dani, L., Gheorghe, K., Ekholm, L., Bottai, M., Tjarnlund, A., & Lundberg, I.E. (2019). Performance of the new EULAR/ACR classification criteria for idiopathic
inflammatory myopathies (IIM) in a large monocentric IIM cohort. Seminars in Arthritis and Rheumatism. https://doi.org/10.1016/j.semarthrit.2019.12.001

24. Lundberg, I. E., Miller, F. W., Tjarnlund, A., & Bottai, M. (2016). Diagnosis and classification of idiopathic inflammatory myopathies. Journal of Internal Medicine, 280(1), 39–51. https://doi.org/10.1111/joim.12524

25. Luu, Q., Day, J., Hall, A., Limaye, V., & Major, G. (2019). External validation and evaluation of adding MRI or extended myositis antibody panel to the 2017 EULAR/ACR myositis classification criteria. ACR Open Rheumatology, 1(7), 462–468. https://doi.org/10.1002acr2.11061

26. Inoue, M., Tanboon, J., Hirakawa, S., Komaki, H., Fukushima, T., Awano, H., Tajima, T., Yamazaki, K., Hayashi, R., Mori, T., Shibuya, K., Yamanoi, T., Yoshimura, H., Ogawa, T., Katayama, A., Sugai, F., Nakayama, Y., Yamaguchi, S., Hayashi, S., … Nishino, I. (2020). Association of dermatomyositis sine dermatitis with anti-nuclear matrix protein 2 autoantibodies. JAMA Neurology, 77(7), 872–877. https://doi.org/10.1001/jamaneurol.2020.0673

27. Mammen, A. L. (2011). Autoimmune myopathies: Autoantibodies, phenotypes and pathogenesis. Nature Reviews Neurology, 7(6), 343–354. https://doi.org/10.1038/nrneurol.2011.63

28. Benveniste, O., Stenzel, W., & Allenbach, Y. (2016). Advances in serological diagnostics of inflammatory myopathies. Current Opinion in Neurology, 29(5), 662–673. https://doi.org/10.1097/WCO.0000000000000376

29. Mariampillai, K., Granger, B., Amelin, O., Guiguet, M., Hachulla, E., Maurier, F., Meyer, A., Tohmé, A., Charuel, J.-C., Musset, L., Allenbach, Y., & Benveniste, O. (2018). Development of a new classification system for idiopathic inflammatory myopathies based on clinical manifestations and myositis-specific autoantibodies. JAMA Neurology, 75(12), 1528–1537. https://doi.org/10.1001/jamaneurol.2018.2598

30. Landis, J. R., & Koch, G. G. (1977). The measurement of observer agreement for categorical data. Biometrics, 33(1), 159–174.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions